AMAG Pharmaceuticals — Proxy Contest (September 2019)
48 slides from AMAG Pharmaceuticals's proxy contest presentation, Sep 4, 2019
Slide 1: Saving AMAG: Urgent Change Needed to Unlock Value
SAVING AMAG: URGENT CHANGE NEEDED TO UNLOCK VALUE SEPTEMBER 2019 WWW.SAVEAMAG.COM
Slide 2: Additional Information
Additional Information 2 • THIS PRESENTATION AND THE VIEWS EXPRESSED HEREIN ARE ONLY TO BE USED TO PROVIDE GENERAL INFORMATION FROM CALIGAN PARTNERS LP AND ITS AFFILIATES (COLLECTIVELY, “CALIGAN”) REGARDING AMAG PHARMACEUTICALS, INC . (“AMAG” OR THE “COMPANY”) . THIS PRESENTATION AND THE VIEWS EXPRE
Slide 3: Executive Summary
Executive Summary 3 • Caligan Partners, LP is one of the largest shareholders of AMAG Pharmaceuticals, owning over 10 % of AMAG’s outstanding shares • Caligan is seeking removal of four incumbent AMAG directors who have seen an average total shareholder return of NEGATIVE 63 . 9 % 2 over their tenur
Slide 4: Caligan's Message to AMAG Shareholders
Caligan’s Message to AMAG Shareholders • Caligan is seeking your support to : • Remove four AMAG directors who have overseen significant value destruction • Elect our four highly qualified Nominees to the Board • To prevent Board entrenchment, Caligan is asking your consent to : • Repeal any provisi
Slide 5: Caligan Nominees For Change
Caligan Nominees For Change 5 Nominees Education Relevant Experience Paul Fonteyne MBA, Carnegie Mellon University MS, Chemical Engineering, University of Brussels • President and CEO of Boehringer Ingelheim USA Corporation • Commercial Leadership Roles, Boehringer Ingelheim, Merck and Co., Inc. and
Slide 6: What Could AMAG Be Worth?
What Could AMAG Be Worth? 6 1 S&P Capital IQ For Consensus Revenue estimates and highest analyst revenue estimates 2 Caligan estimates . High end of the EV/Revenue range consistent with Vifor Pharma EV/Revenue multiple as detailed on slide 17 . For Feraheme International Rights, 26 % global market s
Slide 7: AMAG Has a Collection of Valuable Assets
AMAG Has a Collection of Valuable Assets 7 • Feraheme is a one of two approved high molecular weight IV irons in the US ; 2019 E net sales of $ 170 MM 1 • Feraheme has competitive advantages (substantially lower rates of hypophosphatemia, lower cost per dose) versus its primary competitor, Injectafe
Slide 8: Feraheme Is A Durable, Growing Product
Feraheme Is A Durable, Growing Product 8 • Feraheme is one of six marketed intravenous (IV) iron products in the US and one of two high molecular weight IV irons • Feraheme received a label expansion in February 2018 , based on a non - inferiority study versus Injectafer, which allowed it to expand
Slide 9: Feraheme & Makena Auto-Injector Continue To Grow Market Share
Feraheme & Makena Auto - Injector Continue To Grow Market Share 9 • Post label expansion in February 2018 , Feraheme has continued to increase its share of the IDA market . Caligan believes that, given the hypophosphatemia and cost benefits versus Injectafer , Feraheme has a significant opportunity
Slide 10: Fundamental Problems At AMAG
Fundamental Problems At AMAG 10 AMAG’s Board & Management Have Abysmal TSR AMAG Commercial Spending Needs To Be Rationalized Business Development Has Destroyed Shareholder Value AMAG Management Lacks Credibility No Commercial Synergies Across Portfolio Caligan Action Plan
Slide 11: Underperformance Of Total Shareholder Return Against Any Benchmark
Underperformance Of Total Shareholder Return Over Any Time Period Against Any Relevant Benchmark 11 • AMAG has materially underperformed all of its relevant benchmarks over the last 1 , 2 , 3 , 5 and 10 - year periods • Specifically, AMAG has underperformed the NASDAQ Biotech Index by : • - 393 % ov
Slide 12: Significant Underperformance Over Every Director's Tenure
Significant Underperformance Over The Course Of Every Director’s Tenure 1 12 • AMAG’s total shareholder return has significantly underperformed both the Nasdaq Biotech Index and the S&P 500 over the tenure of every director • Every AMAG director has overseen a significant absolute decline in AMAG sh
Slide 13: Underperformance Versus Peer Set
-100% -50% 0% 50% 100% 150% 200% 250% 300% 350% 400% Underperformance Versus Peer Set 1 13 • Relative to its 2013 and 2018 proxy peer sets, AMAG is the third and second worst performing company in the peer group, respectively • To note, 7 of the 18 companies in the 2013 proxy peer set have sold them
Slide 14: Fundamental Problems At AMAG
Fundamental Problems At AMAG 14 AMAG’s Board & Management Have Abysmal TSR AMAG Commercial Spending Needs To Be Rationalized Business Development Has Destroyed Shareholder Value AMAG Management Lacks Credibility No Commercial Synergies Across Portfolio Caligan Action Plan
Slide 15: Over $1.3 Billion Of Non-Feraheme Capital Invested Resulted In Negative Value
Over $1.3 Billion Of Non - Feraheme Capital Invested Since 2013 Has Resulted In Negative Value To AMAG Shareholders 15 • $ 1 . 38 Bn of shareholder capital has been spent on non - Feraheme related R&D, acquisitions (net of divestitures), and milestone payments from Jan 2012 – June 2019 . The cumulat
Slide 16: Despite 27% CAGR For Feraheme Sales, Market Cap Declined
Despite 27% CAGR For Feraheme Sales, AMAG’s Market Cap Has Declined At A 1% CAGR 16 • Despite AMAG’s only commercial product in 2012 , Feraheme, growing its US revenues at a 27 % CAGR from 2012 – 2019 E, AMAG’s market capitalization has declined at a 1 % CAGR since May 2012 • Additionally, due to th
Slide 17: Comparison With Vifor Highlights Undervalued IV Iron Franchise
- 2,000 4,000 6,000 8,000 10,000 12,000 Vifor IV Iron 2019E Rev Vifor EV - July 2019 - 50 100 150 200 250 300 350 Feraheme 2019E Rev AMAG EV - July 2019 Comparison With Vifor Highlights Undervalued IV Iron Franchise 17 • Feraheme, despite having no international distribution partner, and giving a fo
Slide 18: Comparison With Other Women's Health Companies
• For public companies focused on women’s health, despite having the highest 2020 E consensus revenue, AMAG has (i) a lower enterprise value than both TherapeuticsMD and Obseva and (ii) the worst TSR of the three companies under the tenure of AMAG’s current Board and management • Caligan believes th
Slide 19: Fundamental Problems At AMAG
Fundamental Problems At AMAG 19 AMAG’s Board & Management Have Abysmal TSR AMAG Commercial Spending Needs To Be Rationalized Business Development Has Destroyed Shareholder Value AMAG Management Lacks Credibility No Commercial Synergies Across Portfolio Caligan Action Plan
Slide 20: Commercial Infrastructure And Launch Costs Are Exorbitant Relative To Peers
• As a percentage of revenues, AMAG’s cash SG&A spending is 30 percentage points higher than its next closest peer and 50 percentage points higher than pharmaceutical companies with similar product revenues • AMAG spends more than 90 % of its market capitalization on its commercial infrastructure an
Slide 21: Announced Merger Synergies Never Materialized
• The synergies that AMAG highlighted when pursuing the Lumara and CBR acquisitions have never materialized : • When announcing the Lumara acquisition in September 2014 , AMAG highlighted revenues of $ 180 MM and EBITDA of $ 110 MM and synergies of $ 20 MM . Combined with Feraheme this would imply a
Slide 22: AMAG SG&A Productivity Lowest Of Peers
AMAG SG&A Productivity Lowest Of Peers With >$300MM Product Revenue 22 1 Gross Profit and SG&A from 2014 – 2018 from SEC Filings (S&P Capital IQ). AMAG Gross Profit excludes intangible amortization. Peer group selected as companies with >$300MM of product revenue in 2015 and consensus estimates of >
Slide 23: AMAG's Women's Health Sales Force Productivity Is Poor
AMAG’s Women’s Health Sales Force Productivity Is Poor • While the productivity of AMAG’s sales representatives that are dedicated to Feraheme is in - line with pharmaceutical and biotech company averages, the productivity of AMAG’s sales representatives focused on women’s health (post - AMAG’s sale
Slide 24: Pipeline & Spending Remain Overhang With Investment Community
Pipeline & Spending Remain Overhang With Investment Community 24 Analyst Date Jefferies May 7 , 2019 “It is hard to be encouraged by the potential of the pipeline when AMAG narratives have repeatedly failed to pan out . Currently trading at ~ 1 x 2019 revenue, its valuation largely reflects the Stre
Slide 25: Fundamental Problems At AMAG
Fundamental Problems At AMAG 25 AMAG’s Board & Management Have Abysmal TSR AMAG Commercial Spending Needs To Be Rationalized Business Development Has Destroyed Shareholder Value AMAG Management Lacks Credibility No Commercial Synergies Across Portfolio Caligan Action Plan
Slide 26: AMAG Management Has Consistently Missed Expectations
AMAG Management Has Consistently Missed Expectations 26 Product Public Statement 2019E Revenues 1 MuGard “In terms of product potential, there are estimated to be around 400 , 000 patients each year who’re at risk of developing oral mucositis, so it's a fairly significant market and using numbers li
Slide 27: Long-Term Credibility Gap
Long - Term “Credibility” Gap • Setting and consistently meeting expectations is essential to building trust with the investment community . AMAG’s missed expectations on every product acquisition have completely eroded analyst confidence in AMAG forecasts . There is a $ 216 MM gap between consensus
Slide 28: Short-Term Credibility Gap
Short - Term “Credibility” Gap • Even on a short - term basis, the market’s consensus revenue estimates for AMAG are lower than AMAG’s low - end of its guidance range, the 2 nd lowest for any biotech or pharmaceutical company with at least $ 300 MM of consensus revenue estimates . This delta highlig
Slide 29: AMAG Trades At Lowest EV/Revenue Multiple Of Peers
0x 1x 2x 3x 4x 5x 6x 7x 8x PTCT NTRA HARV IRWD CHRS SUPN PCRX CORT TSX:ADVZ AMPH PAHC LCI AKRX OPK AMAG AMAG Trades At Lowest EV/Revenue Multiple Of Biotech and Pharmaceutical Companies With Greater Than $300MM of Revenue 29 1 TEV < $2.5Bn; Estimated Forward Product Revenues > $300MM as of July 31,
Slide 30: Fundamental Problems At AMAG
Fundamental Problems At AMAG 30 AMAG’s Board & Management Have Abysmal TSR AMAG Commercial Spending Needs To Be Rationalized Business Development Has Destroyed Shareholder Value AMAG Management Lacks Credibility No Commercial Synergies Across Portfolio Caligan Action Plan
Slide 31: AMAG's Public Statements Confirm No Portfolio Synergies
AMAG’s Public Statements Confirm No Portfolio Synergies 31 Product Public Statement Makena “And so, large sales force, about 110 reps out there , calling on the OB/GYNs . Very good, sort of stickiness within the supply chain and reimbursement channel . Good connections to the payers . ” – Ed Myles,
Slide 32: AMAG's Disparate Portfolio Provides No Leverage On Commercial Infrastructure
- 100 200 300 400 500 600 - 50 100 150 200 250 300 350 2015 2016 2017 2018 2019E Revenues ($MM) Cash SG&A ($MM) Compensation & Benefits Professional, Consulting, Other Outside Revenues AMAG’s Disparate Therapeutic Portfolio Provides No Leverage On Existing Commercial Infrastructure • To launch Intra
Slide 33: Caligan Action Plan
Fundamental Problems At AMAG 33 AMAG’s Board & Management Have Abysmal TSR AMAG Commercial Spending Needs To Be Rationalized Business Development Has Destroyed Shareholder Value AMAG Management Lacks Credibility No Commercial Synergies Across Portfolio Caligan Action Plan
Slide 34: Caligan Action Plan: Actions and Rationale
34 Action Rationale Significant Board Refreshment • Given AMAG’s absolute and relative underperformance, AMAG would benefit from the fresh perspective of a new set of independent directors that includes both (i) directors with significant pharmaceutical expertise and public company experience and (i
Slide 35: AMAG Directors Have Purchased an Immaterial Number of Shares
AMAG Directors Have Purchased an Immaterial Number of Shares 1 35 • AMAG’s directors own an immaterial amount of shares (< 0 . 50 % ) and, over the last 7 years, only one director has purchased shares worth ~ $ 100 k . Caligan owns over 10 % of AMAG’s shares . • As AMAG shareholders have lost ~ 50 %
Slide 36: AMAG Board Should Explore Whether Separating Assets Will Create Value
AMAG Board Should Explore Whether Separating Assets Will Create Value 36 1 Consensus estimates 2 Caligan estimates 3 1Q2019 Earnings Call 4 2Q2018 Earnings Call; pre - sales force consolidation Nephrology/Hematology Women’s Health Feraheme Pipeline 2019E Revenues 1 $170MM N/A 2019E EBITDA 2 $100MM $
Slide 37: SG&A Should Be Reduced Immediately
SG&A Should Be Reduced Immediately 37 1 Consensus revenue estimates. SG&A is last quarter annualized. Best - In - Class is Amphastar Pharmaceuticals. Peer Average is US public pharmaceutical and biotech companies that are expected to generate between $300MM and $600MM of product revenue in 2020 2 Ex
Slide 38: AMAG Needs An International Distribution Partner For Feraheme
AMAG Needs An International Distribution Partner For Feraheme 38 1 S&P Capital IQ For Consensus Estimates 2 26% global market share on $413MM of ex - US Ferinject sales equals $119MM of ex - US Feraheme revenue. At a 33.33% royalty rate, AMAG would receive $39.7MM annually. At a 3x – 7x capitalizati
Slide 39: Caligan's Research on AMAG Pharmaceuticals
Caligan’s Research on AMAG Pharmaceuticals • Caligan has conducted exhaustive research over the past 18 months to better understand AMAG’s products and strategy, including working with respected former pharmaceutical executives to diligence each of AMAG’s products • Caligan has worked with leading n
Slide 40: About Caligan Partners
About Caligan Partners 40 Caligan Partners, LP was founded by David Johnson and Sam Merksamer in 2017 to pursue a deep value - oriented investment strategy Caligan’s principals have extensive experience working closely with management teams on strategic and operating initiatives, and working through
Slide 41: Contacts & Additional Information
Contacts & Additional Information 41 Investors Edward McCarthy/ Geoffrey Weinberg D . F . King & Co . , Inc . + 1 ( 212 ) 269 - 5550 AMAG@dfking . com Press Robert Laman Caligan Partners + 1 ( 646 ) 859 - 8205 rl@caliganpartners . com F or Additional Information IR@caliganpartners . com LEGEND Calig
Slide 42: Website home page: Urgent change needed to restore value to AMAG shareholders
Slide 43: Board Nominees: Paul Fonteyne
PRESENTATI BOARD NOMINEES BOARD NOMINEES Paul Fonteyne Paul Fonteyne, 57, most recently served as the Chairman of BI USA, a biotechnology % company, and President of Animal Health for Boehringer-Ingelheim USA Corporation one of the world’s largest pharmaceutical companies, in 2018. Prior to that rol
Slide 44: Board Nominees: Lisa Gersh
HOME TATION BOARD NOMINEES Lisa Gersh Lisa Gersh, 60, was most recently the Chief Executive Officer of Alexander Wang, a major fashion brand. Prior to joining Alexander Wang, Ms. Gersh served as the Chief Executive Officer of Goop, Inc. a lifestyle brand fourded by Gwyneth Paltrow. From 201 until 20
Slide 45: David Johnson
David Johnson David Johnson, 37, Is a Partner and co-Founder of Caligan Partners LP, an investment manager. Previously, Mr. Johnson was a Managing Director at The Carlyle Group, where he was employed from 2010 - 2017. At Carlyle, Mr. Johnson was involved in many of the firm's strategic initiatives a
Slide 46: About Caligan
NOMINEES ABOUT CALIGAN ABOUT CALIGAN Caligan Partners, LP was founded by David Johnson and Sam Merksamer in 2017 to pursue a deep value- oriented investment strategy Caligan's principals have extensive experience working closely with management teams on strategic and operating initiatives, and worki
Slide 47: Contact
CONTACT INVESTOR CONTACT: CONTACT US Edward MoCarthy & Geofrrey Weinberg DF. King & Co, Inc. +1 (212) 269-5550 AMAGadiKingcom GENERAL INQUIRIES MEDIA CONTACT: Name" Robert Laman Caligan Partners LP First Name Last Name +1 (646) 859-8205 Email rl@caliganpartners.com Message"
Slide 48: Exhibit: Item 4. Purpose of Transaction
Exhibit 4 Item 4. PURPOSE OF TRANSACTION Item 4 of the Schedule 13D is hereby amended and supplemented by the addition of the following: On September 4, 2019, the Reporting Persons filed a preliminary consent statement (the " Preliminary Consent Statement ") in connection with its solicitation of wr
AMAG Pharmaceuticals — Proxy Contest (September 2019) on 6ix